October 06, 2026 article Open access Reprogramming the tumor microenvironment in mesothelioma: from immune suppression to therapeutic opportunity Frontiers in Immunology DOI: 10.3389/fimmu.2026.1814514 Full text (OA) OpenAlex Authors 0 Author list not loaded yet. Cited by 0 stored of 0 References 4 Search Sort Most cited Newest Oldest Patent citations Title Any typearticle review book-chapter conference-paper preprint dissertation book dataset other Any fieldAgricultural and Biological Sciences Arts and Humanities Biochemistry, Genetics and Molecular Biology Business, Management and Accounting Chemical Engineering Chemistry Computer Science Decision Sciences Dentistry Earth and Planetary Sciences Economics, Econometrics and Finance Energy Engineering Environmental Science Health Professions Immunology and Microbiology Materials Science Mathematics Medicine Neuroscience Nursing Pharmacology, Toxicology and Pharmaceutics Physics and Astronomy Psychology Social Sciences Veterinary Open access First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial 2021 The Lancet article Medicine Occupational and environmental lung diseases Open access cited by 4 patents 1,233 citations First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 2022 Annals of Oncology article Medicine Occupational and environmental lung diseases Open access 266 citations Pleural mesothelioma 2025 Nature Reviews Disease Primers review Medicine Occupational and environmental lung diseases 28 citations Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743 2026 Journal of Clinical Oncology article Medicine Occupational and environmental lung diseases Open access 7 citations 4 results